CD8A and diabetes mellitus: The difference is that systemic JAK inhibitor treatment also inhibits the response of CD8+ T cells to γc cytokines and likely inhibits responses of other immune cells, such as inflammatory macrophages, APCs and NK cells, to cytokines, affecting their ability to contribute to diabetes pathogenesis (Figure 1).